Sami Corwin
Stock Analyst
(n/a)
# 1,423
Out of 4,648 analysts
6
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sami Corwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNYA Tenaya Therapeutics | Initiates: Outperform | n/a | $2.57 | - | 1 | Jun 10, 2024 | |
| NGNE Neurogene | Initiates: Outperform | n/a | $67.41 | - | 1 | Mar 21, 2024 | |
| MESO Mesoblast | Downgrades: Market Perform | n/a | $8.51 | - | 1 | Aug 4, 2023 | |
| CRSP CRISPR Therapeutics AG | Reinstates: Outperform | $75 | $51.46 | +45.74% | 1 | May 30, 2023 | |
| LEGN Legend Biotech | Initiates: Market Perform | n/a | $43.84 | - | 1 | May 25, 2023 | |
| QURE uniQure | Initiates: Outperform | $66 | $5.71 | +1,055.87% | 1 | Oct 27, 2021 |
Tenaya Therapeutics
Jun 10, 2024
Initiates: Outperform
Price Target: n/a
Current: $2.57
Upside: -
Neurogene
Mar 21, 2024
Initiates: Outperform
Price Target: n/a
Current: $67.41
Upside: -
Mesoblast
Aug 4, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.51
Upside: -
CRISPR Therapeutics AG
May 30, 2023
Reinstates: Outperform
Price Target: $75
Current: $51.46
Upside: +45.74%
Legend Biotech
May 25, 2023
Initiates: Market Perform
Price Target: n/a
Current: $43.84
Upside: -
uniQure
Oct 27, 2021
Initiates: Outperform
Price Target: $66
Current: $5.71
Upside: +1,055.87%